A case of cancer-associated hyponatraemia: primary adrenal insufficiency secondary to nivolumab

CONCLUSION: Physicians need to be aware of potential immune-related adverse events in all patients treated with an immune checkpoint inhibitor. Their timely recognition is essential to carry out the proper treatment.PMID:34238203 | DOI:10.2174/1871530321666210708142815

Source: Endocrine, Metabolic and Immune Disorders Drug Targets - July 9, 2021 Category: Endocrinology Authors: Silvia Galliazzo Filippo Morando Paola Sartorato Michela Bortolin Ernesto De Menis Source Type: research